Royalty Pharma Strengthens Board with Vlad Coric Appointment
Company - People | Apr 08, 2025 | RP Management LLC
Royalty Pharma plc has announced the appointment of Vlad Coric, M.D., to its Board of Directors, effective immediately. Dr. Coric, who currently serves as the Chairman and CEO of Biohaven, brings extensive experience from the biopharmaceutical sector, particularly with his background in drug discovery and commercialization in several therapeutic areas including neuroscience and oncology. He led Biohaven through significant achievements, notably the FDA approval of Nurtec ODT and the company's sale to Pfizer for $13 billion. Royalty Pharma’s CEO, Pablo Legorreta, emphasizes that Dr. Coric's experience in the royalty funding space, coupled with his leadership and scientific expertise, will be invaluable to the company's mission of leading innovation funding in life sciences. Royalty Pharma, founded in 1996, is renowned for acquiring biopharmaceutical royalties and has built a diverse portfolio of royalties from top-performing therapies.
Sectors
- Biopharmaceutical
- Finance
Geography
- United States – Royalty Pharma is based in New York, NY, and Vlad Coric's career highlights, including the acquisition of Biohaven, emphasize activities within the U.S.
Industry
- Biopharmaceutical – The article discusses Royalty Pharma and its focus on acquiring biopharmaceutical royalties, making the biopharmaceutical industry central to the content.
- Finance – Royalty Pharma is involved in the finance sector, specifically in funding innovation across the biopharmaceutical industry by acquiring royalties and co-funding clinical trials.
Financials
- $13 billion – The total consideration for Biohaven's sale to Pfizer.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Royalty Pharma plc | Company appointing Vlad Coric to its Board | Company | Royalty Pharma is a leading buyer of biopharmaceutical royalties and innovator funder, founded in 1996. |
| Vlad Coric, M.D. | Newly appointed Board member | Person | CEO of Biohaven with extensive experience in biopharma, including development and commercialization of neuro and oncology treatments. |
| Biohaven | Company led by Vlad Coric | Company | A biopharmaceutical company focused on treatments in neuroscience, immunology, and oncology. |
| RP Management LLC | PE firm associated with the article | Company | The private equity firm mentioned in the article's source header. |
| Pfizer | Purchaser of Biohaven | Company | A global pharmaceutical corporation that acquired Biohaven for $13 billion. |